TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants without Graft Versus Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in % patients feeling in control of their decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in number of Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in % patients with advance directives for kidney care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: LPC index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Cardiac Fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin sensitivity/insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional assessment (faecal continence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Safety Assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Oncological safety assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical presentation of chronic thromboembolic pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to cancer diagnosis or recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Psychometric properties of KHQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychometric properties of ICIQ-SF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Overall Lifting and Tightening of the Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Seroconversion rates at month 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: leukotriene levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of cases requiring cessation of Ventil use
Endpoint domain: Adverse events/effects
Primary endpoint: Presence and characteristics of fibrous septa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Activation Measure- Mental Health (PAM-MH)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Altarum Consumer Engagement (ACE) Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trust and Satisfaction Survey Responses Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change from Baseline in fracture management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Change from Baseline in adhesions development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Change from Baseline in vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean Change from Baseline in Pain Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: IOP fluctuation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: pregnancy rates of HIV+ DMPA-users on EFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: pregnancy rates of HIV+ LNG implant users on EFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: HIV viral load from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pelvic floor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastasis recti abdominis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbopelvic pain/disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of patients with Nephrocheck score > 0.3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference from baseline in Plasma aldosterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Corneal features measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of adherence to medical regimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Substance use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mental health concerns
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent reduction in the frequency of monthly migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of CSID Genetic Variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-year mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: one-year procedure-related severe adverse event rates
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of Implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ease of Implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to first exacerbation event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of adherent days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Patients Contacted for Quitline Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oral glucose tolerance test (OGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: questionnaire response rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: percentage of those eligible who consented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number and reasons for withdrawal
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: session attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: session adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: responses on an evaluation questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Infant Length-for-Age Z-Scores with Prenatal Supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Length-for-Age Z-Scores with Postpartum Supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in anxiety and depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oncological safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects with drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Pain Score During IUD Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Localisation and precision of the tip of the endotracheal tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Plasma Levels of Fasting Trimethylamine-N-oxide (TMAO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Platelet Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progesterone levels on the day of embryo transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: adequate clinical and Parasitological response (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Non-Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: differences in abundance of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of new or enlarging cerebral MRI T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: serum and skin levels of carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SER development of at least -1.0 dioptres (D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SER development of at least -0.5 dioptres (D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritable Bowel Syndrome (IBS) symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Remission of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of plaque disruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attendance at postpartum visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of treatment recommendations for depression
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Degree of patient satisfaction with interaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall patient experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Levels of pro-inflammatory and bone mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Canadian Diabetes Risk (CANRISK) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Summed Pain Intensity Differences (SPID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in post traumatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients experiencing rapidly progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: proportion of patients experiencing increase in seizures, stroke, and infection
Endpoint domain: Adverse events/effects
Primary endpoint: Melatonin phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Core body temperature phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buccal cell mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of lower extremity peripheral arterial disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Remission of perianal fistulising Crohn's
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Impact on microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability (AUC0-t) of Total Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability (Cmax) of Total Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medium Dose TBS-2 Multiple Dose Average Steady-state Concentration (Cavg) of Total Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emboli and Hypoperfusion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach 90% of maximum cortical blood oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of subjects with self-perceived gluten-sensitivity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants with Mayo Endoscopic Sub-score = 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Magnitude of Graft Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hypertension Self-Care Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline Fatty Acid profile of the erythrocyte membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 10-year Framingham CVD risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with Viral Load <50 cp/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CR Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Insulin aspart specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Human insulin specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cross reacting antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in glucose-sensitivity of the beta cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of Atazanavir (ATV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Cobicistat (COBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time Curve from time zero extrapolated to infinite time (AUC(INF)) of ATV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(INF) of COBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoglobulin G (IgG) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunoglobulin M (IgM) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Opsonophagocytic Killing Activity (OPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of functional gastrointestinal disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Eligible Participants Recruited to the Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Randomized Participants Who Complete Intervention Components
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction Ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of ventilator free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Triglycerides to High Density Lipoprotein Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient-centered assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cochin score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Total Rhinoconjunctivitis Symptom Score (TRSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein digestibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stimulated saliva production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the diagnostic classifier
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (PFS) Rate at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Cortical cataract opacification grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LAVI (left atrial volume index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of circulating DNA (ctDNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of ultrasound lung rockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seroconversion rate (IIV4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate (PPV23)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration (GMC) (IIV4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration (GMC) (PPV23)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Overall Exacerbations of E-RS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Clinically Evaluable Patients With Clinical Response of Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ICU Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in Functional Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants With Clinically Significant CMV Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cancer Cell Protein Levels of HER Family Members
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lifespan of Effector CD8 T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lifespan of Monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response to albuterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD fMRI activation in motor cortex during isometric hand grip tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BOLD fMRI vascular reactivity to a breath-hold task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate at 12 months after IMP application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with HBV viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Preeclampsia necessitating delivery at gestational age < 37 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Number of Device and/or Procedure-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Fat Layer of the Treated Area as Measured by Ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety, clinically
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical description of the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EVENDOL scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in EDIN scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NFCS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 6-Minute Walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in symptoms of atrophic vaginitis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in disability of the arm, shoulder and hand (DASH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractority of the median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Local tumor control in the ipsilateral breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lived experience of older people receiving ICCI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lived experience of professionals delivering ICCI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participation in Physical Activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of Adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of PMZ-2010 related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Psoriasis Severity Index (PSI) at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearing Percentage of Target Plaque Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Improvement Compared to Baseline in the Target Plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EGFR gene sequence comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low back pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes